ReviewDrug, healthcare and patient safety2017
Update on the usage and safety of epinephrine auto-injectors, 2017.
Review in Drug, healthcare and patient safety, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 47 citations in OpenAlex.
- Reversal of Fentanyl-Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene Administered by Auto-Injector Versus Intranasal Naloxone.Journal of clinical pharmacology · 2025Trial
- Comparison of Systemic Exposure Between Epinephrine Delivered via Metered-Dose Inhalation and Intramuscular Injection.Journal of aerosol medicine and pulmonary drug delivery · 2025Trial
- Real-World Shelf Life of Epinephrine Auto-Injectors in Canada: Implications for Renewal Frequency and Patient Burden.Journal of market access & health policy · 2026Article
- Epinephrine Underuse for Anaphylaxis in Infants and Toddlers: A Practical Review for Pediatricians.Paediatric drugs · 2026Review
- Real-World Shelf Life of Adrenaline Auto-Injectors at Pharmacies in Denmark, Finland, Sweden, and Norway.Journal of market access & health policy · 2026Article
- Optimizing Adrenaline Administration in Anaphylaxis: Clinical Practice Considerations and Safety Insights.Clinical and translational allergy · 2025Review
- National best practice guidelines for anaphylaxis prevention and management in Australian schools.The journal of allergy and clinical immunology. Global · 2025Article
- Significant handling errors and education gaps regarding the use of the emergency kit among adult patients with Hymenoptera venom allergy.Allergologie select · 2025Article
- Article
- Article
- Level of knowledge among healthcare professionals regarding anaphylaxis.Asia Pacific allergy · 2022Article
- Autoinjector - A smart device for emergency cum personal therapy.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2021Review
- [Paediatric Life Support].Notfall & rettungsmedizin · 2021Review
- Reversal of Digital Ischemia with Phentolamine After Accidental Epinephrine Injection.The American journal of case reports · 2020Article
- Effects of Intranasal Epinephrine on Cerebrospinal Fluid Epinephrine Pharmacokinetics, Nasal Mucosa, Plasma Epinephrine Pharmacokinetics, and Cardiovascular Changes.Pharmaceutical research · 2020Article
- Intranasal epinephrine effects on epinephrine pharmacokinetics and heart rate in a nasal congestion canine model.Respiratory research · 2020Article
- Intranasal epinephrine in dogs: Pharmacokinetic and heart rate effects.Pharmacology research & perspectives · 2020Article
- Epinephrine delivery via EpiPenClinical and translational allergy · 2020Article
- Knowledge of allergies and performance in epinephrine auto-injector use: a controlled intervention in preschool teachers.European journal of pediatrics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaphylaxis is a serious, potentially fatal allergic reaction. Guidelines recommend prompt intramuscular injections of epinephrine as the first-line therapy for anaphylaxis. Delayed epinephrine treatment may cause undesirable clinical outcomes, including death. In the community, epinephrine auto-injectors (EAIs) are commonly used to treat anaphylaxis. This literature review examines several recent concerns regarding the safety of EAIs that may prevent the timely administration of epinephrine. Reports of cardiovascular complications are linked with epinephrine administration, although recent studies suggest that these events are much more commonly associated with intravenous epinephrine rather than with EAIs. Recent studies have also highlighted accidental injections of EAIs in patients' or caregivers' fingers and lacerations associated with the use of EAI in children. However, the data suggest that both accidental injections and lacerations are rare and require limited medical intervention. In addition, patients may receive conflicting information on the safety and efficacy of using expired EAIs. Overall, it is believed that the benefits of using EAIs far outweigh the potential risks of not administering an EAI. Although legitimate safety concerns are associated with EAIs, adverse events are rare. Continued training of medical providers, caregivers, and patients may be beneficial to address these concerns and reduce EAI-associated injuries while ensuring that patients receive necessary medical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.